中危前列腺癌放疗患者雄激素剥夺治疗使用趋势
该回顾性队列研究分析国家癌症数据库中2004至2016年诊断为中危前列腺癌并接受放疗的108185例男性,描述人口学、临床和社会经济因素与雄激素剥夺治疗(ADT)使用的关联。结果显示41.09%接受ADT,有利中危组32.06%接受ADT,不利中危组52.64%接受ADT。多因素分析显示ADT使用与年龄、诊断年份、非白人种族、政府保险、较高前列腺特异性抗原、肿瘤分期、Gleason评分、非学术中心及单纯外照射放疗相关。
要点
- 108185例中危前列腺癌放疗患者中41.09%接受ADT
- 有利中危组ADT使用率32.06%,不利中危组52.64%
- ADT使用与年龄、诊断年份、种族、保险、PSA、分期、Gleason评分、中心类型及放疗方式相关
核心结论
- 中危前列腺癌根治性放疗患者中ADT使用存在差异,数据提示多种临床和社会经济差异影响其使用。
- 相当比例的有利中危前列腺癌患者接受ADT,仍为治疗降级的候选人群;相当比例的不利中危前列腺癌患者可能因省略ADT而治疗不足。
研究设计与样本
- 回顾性队列研究,分析国家癌症数据库中2004至2016年诊断为中危前列腺癌并接受放疗的108185例男性。
主要发现
- 108185例中危前列腺癌放疗患者中41.09%接受ADT。
- 有利中危组60705例中32.06%接受ADT,不利中危组47480例中52.64%接受ADT。
- 多因素分析显示ADT使用与年龄、诊断年份、非白人种族、政府保险、较高PSA水平、肿瘤分期、Gleason评分、非学术中心治疗及单纯外照射放疗相关。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Until 2018, National Cancer Comprehensive Network guidelines recommended androgen deprivation therapy (ADT) for all men with intermediate-risk prostate cancer who had undergone radiation therapy. Intermediate risk was stratified as favorable and unfavorable in 2018, and ADT recommendation was limited to men with unfavorable intermediate-risk prostate cancer. Data suggesting this stratification and treatment deintensification were first published in December 2013. This study characterizes US national trends for demographic, clinical, and socioeconomic factors associated with ADT use in men with intermediate-risk prostate cancer who have undergone definitive radiation therapy. METHODS AND MATERIALS: This retrospective cohort study examined 108,185 men in the National Cancer Database who were diagnosed with intermediate-risk prostate cancer from 2004 to 2016. Temporal trends in demographic, clinical, and socioeconomic factors among men with intermediate-risk prostate cancer and associations with the use of ADT were characterized. RESULTS: In total, 108,185 men diagnosed with intermediate-risk prostate cancer underwent radiation therapy from 2004 to 2016. Of these men, 41.09% received ADT. Among the 60,705 men with favorable intermediate-risk prostate cancer, 32.06% received ADT. Among the 47,480 men with unfavorable intermediate-risk prostate cancer, 52.64% received ADT. On multivariate analysis, use of ADT was associated with age and year of diagnosis; being a race other than White; having government-based insurance; having a higher prostate-specific antigen level, tumor stage, and Gleason score; receiving treatment at a nonacademic center; and receiving external beam radiation therapy alone. CONCLUSIONS: The findings highlight that ADT use is variable in men undergoing definitive radiation therapy for intermediate-risk prostate cancer, with the data suggesting that several clinical and socioeconomic disparities influence its use. The findings suggest that a significant proportion of men with favorable intermediate-risk prostate cancer receive ADT and remain candidates for treatment de-escalation, whereas a significant proportion of men with unfavorable intermediate-risk prostate cancer may be undertreated when ADT is omitted.
引用
- Agrawal V, Ma X, Hu JC, et al. Trends in Androgen Deprivation Use in Men With Intermediate-Risk Prostate Cancer Who Underwent Radiation Therapy. Adv Radiat Oncol. 2022. PMID: 35814856. doi:10.1016/j.adro.2022.100904
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。